CoChat

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Sequist, Lecia V., Joshi, Victoria A., Jänne, Pasi A., Bell, Daphne W., Fidias, Panos, Lindeman, Neal I., Louis, David N., Lee, Jeffrey C., Mark, Eugene J., Longtine, Janina, Verlander, Peter, Kucherlapati, Raju, Meyerson, Matthew, Haber, Daniel A., Johnson, Bruce E., Lynch, Thomas J. · 2006 · Clinical Cancer Research
Cited by 81

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

As the literature about epidermal growth factor receptor (EGFR) mutations grows and screening for mutations becomes increasingly integrated into clinical care, it is important to examine how best to do somatic mutational analyses and how best to use the test results in clinical decision making. We began offering mutation screening by comprehensive direct sequence analysis of exons 18 to 24 of the tyrosine kinase domain of EGFR in August 2004 as part of clinical cancer care and protocol therapy at our institutions. All identified potential mutations are confirmed with three to five independent PCRs of the original genomic DNA sample and, if not previously noted in the literature, are compared with the patient's germ-line DNA to ensure the finding is somatic. We formally analyzed the first 100 patients to undergo EGFR sequence analysis and found that testing was feasible and significantly affected the treatment of patients with non–small cell lung cancer (NSCLC). Patients harboring EGFR mutations were significantly more likely to receive recommendations for therapy with EGFR tyrosine kinase inhibitors (i.e., gefitinib or erlotinib) than patients without mutations. However, negative EGFR test results did not prevent physicians from administering these agents to selected patients. Ideally, a standardized technique for mutation testing could be developed, with demonstrated reproducibility and validity. Clinical trials incorporating molecular diagnostics are ongoing to assess the efficacy of EGFR tyrosine kinase inhibitors as first-line therapy for metastatic NSCLC and as adjuvant therapy for early-stage resected NSCLC. It is likely that mutation testing and other molecular analyses will be most useful in these two clinical situations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-0099

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 81

Metadata

Authors
Sequist, L. V., Joshi, V. A., Jänne, P. A., Bell, D. W., Fidias, P., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., Verlander, P., Kucherlapati, R., Meyerson, M., Haber, D. A., Johnson, B. E., & Lynch, T. J.
Venue
Clinical Cancer Research
Published
2006-07-15
Volume
12
Issue
14
Pages
4403s-4408s
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2124214040
Cited by
81
References
4
FWCI
7.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-0099
The paper
Sequist, L. V., Joshi, V. A., Jänne, P. A., Bell, D. W., Fidias, P., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., Verlander, P., Kucherlapati, R., Meyerson, M., Haber, D. A., Johnson, B. E., & Lynch, T. J. (2006). Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-0099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.